Ewelina Kulikowski

Ewelina Kulikowski serves as Chief Scientific Officer at Resverlogix, where she directs the company's scientific strategy, contributes to commercialization and lifecycle planning, and oversees al research and development activities. Dr. Kulikowski is also Resverlogix' primary scientific communicator. She shares the latest program developments in presentations at scientific conferences, as well as in discussions with investors and partners. Since joining the company in 2005, Dr. Kulikowski has contributed to the development of lead drug apabetalone (RVX-208) from its discovery, through preclinical evaluation, an investigational new drug application, and the completion of multiple human clinical studies. She led projects that demonstrated apabetalone's therapeutic potential in vascular disease, pulmonary hypertension, muscular dystrophy, and COVID-19, as well as projects that uncovered apabetalone's unique epigenetic mechanism of action. This work resulted in the publication of over 25 peer-reviewed articles and numerous successful patent applications. Dr. Kulikowski holds a Doctorate in Oncology from the University of Calgary, Alberta. She enjoys cycling and hiking, is fluent in Polish and an active member of the Calgary Polish community.